The struggling psychedelics firm abandoned direct patient care in favor of developing tech for insurance reimbursement and ...

It just feels like it didn’t have to come to this. I feel like, as a father, I waited way too long for insurance to give us a ...

Atai Life Sciences N.V. ( (ATAI) ) has released its Q3 earnings. Here is a breakdown of the information Atai Life Sciences N.V. presented to ...

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Some other lung-related conditions known to cause chest discomfort include: Pneumonia: This infection inflames the air sacs ...

Atai Life Sciences reports Q3 results, highlighting FDA clearance for DMT film, upcoming MDMA trials, and a strong cash position.

"Our unique Phase 3 pivotal program design has been informed by the impressive Phase 2 (four-month) data showing rapid, ...

One in five adults said they experienced any symptoms of anxiety or depression in a 2-week period, according to a 2022 CDC ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revoluti ...